First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening
- Concomitant treatment with MTX (7.5 - 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing
Exclusion Criteria:
- Subjects with chronic inflammatory autoimmune disease other than RA
- History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease
- Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation
- Clinically significant cardiac or cardiovascular disease
- Past or current malignancy
- Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test (test can be performed up to 2 months prior to dosing). One retest is allowed in case of inconclusive results.- A history of active TB within the last 3 years even, if treated effectively. - A history of active TB more than 3 years ago, if there is no documentation that the prior anti-TB treatment was appropriate in duration and type
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Administered i.v.(intravenous) or s.c.
(subcutaneous, under the skin).
|
|
EXPERIMENTAL: Active
|
I.v.(intravenous) dose-escalation.
Highest dose planned for i.v.
administration is 10 mg/kg
The s.c.
(subcutaneous, under the skin) part will not start until at least two i.v.
dose levels have been evaluated for safety and pharmacokinetics.
Highest dose planned for s.c.
administration is 4 mg/kg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of adverse events (AEs)
Time Frame: Up to 10 weeks after trial product administration
|
Up to 10 weeks after trial product administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
I.v. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
I.v. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
S.c. administration: AUC, Area under the curve
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
S.c. administration: terminal half-life (t½)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
Maximum level and duration of full C5a receptor (C5aR) occupancy by NNC0215-0384 on neutrophils
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
|
Maximum and minimum levels of relevant serum and plasma biomarkers related to NNC0215-0384 safety, efficacy or mechanism of action (MoA)
Time Frame: Up to 10 weeks after drug administration
|
Up to 10 weeks after drug administration
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN8210-3926
- 2011-003008-19 (EUDRACT_NUMBER)
- U1111-1122-3474 (OTHER: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.